Free Newsletter
Statins may keep asthma patients out of ER
Statins may have yet another target: Asthma. A new study by Medco Health Solutions and Brigham and Women's Hospital found that asthma patients who add statins to their asthma-drug therapy have to visit the ER less often. And they're hospitalized less often, too.
Adults who used inhaled corticosteroids and also took statins--such as Pfizer's Lipitor and AstraZeneca's Crestor--cut their risk of hospitalization or an ER visit by one-third, Medco said. The pharmacy benefits manager based its research on a retrospective review of members' records. All statins were treated equally; in other words, results weren't broken out by which type of statin patients used.
In addition to lowering cholesterol, statins have anti-inflammatory properties. These might play a role in helping lower the incidence of asthma attacks, Dow Jones reports. That's because asthma involves swelling of the airways, as well as constriction of muscles in the bronchial passages. Medco plans to present the study at the American Academy of Allergy Asthma and Immunology meeting.
Statins aren't FDA-approved for asthma treatment, and this wasn't a rigorous trial. "Don't rush out and buy yourself a statin for your asthma today," Dr. Robert Epstein, Medco's chief medical officer, told Dow Jones.
- check out the release
- read the Dow Jones story
Related Articles:
Statins lower stroke severity, improve recovery
Study: Statins stave off arterial aging
Study: Statins don't cause cancer
Pediatricians say kids should take statins
Study: Diabetics should take statins
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: